Sian Yik Lim
Overview
Explore the profile of Sian Yik Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
216
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sawada H, Dang J, Saha B, Taylor L, Nishimura Y, Kahili-Heede M, et al.
BMC Rheumatol
. 2024 Sep;
8(1):43.
PMID: 39277771
Background: To summarize clinical presentations, baseline characteristics, diagnosis, treatment, and treatment outcomes through a systematic review of cases of crystal-induced arthritis in prosthetic joints in the literature. Methods: A systematic...
2.
Taylor L, Matsunaga M, Ahn H, Siu A, Lim S
Osteoporos Int
. 2024 Jul;
35(11):1931-1941.
PMID: 39080035
Purpose: To estimate mortality rates and identify specific risk factors associated with 1-year mortality after osteoporotic hip fracture in Hawai'i. Methods: A retrospective review of adults (≥ 50 years) hospitalized...
3.
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, et al.
Arthritis Rheumatol
. 2024 Jul;
76(8):1182-1200.
PMID: 38978310
Objective: We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods: We developed clinically relevant population, intervention, comparator, and...
4.
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, et al.
Arthritis Care Res (Hoboken)
. 2024 Jul;
76(8):1051-1069.
PMID: 38973731
Objective: We provide evidence-based recommendations regarding the treatment of interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases (SARDs). Methods: We developed clinically relevant population, intervention, comparator, and...
5.
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, et al.
Arthritis Care Res (Hoboken)
. 2024 Jul;
76(8):1070-1082.
PMID: 38973729
Objective: We provide evidence-based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic...
6.
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, et al.
Arthritis Rheumatol
. 2024 Jul;
76(8):1201-1213.
PMID: 38973714
Objective: We provide evidence-based recommendations regarding screening for interstitial lung disease (ILD) and the monitoring for ILD progression in people with systemic autoimmune rheumatic diseases (SARDs), specifically rheumatoid arthritis, systemic...
7.
Thorne T, Nishioka S, Wong K, Lawton D, Lim S, Nakasone C
Arch Orthop Trauma Surg
. 2024 Mar;
144(5):1937-1944.
PMID: 38536508
Background: Previous arthroplasty utilization research predominantly examined Black and White populations within the US. This is the first known study to examine utilization and complications in poorly studied minority racial...
8.
Chang C, Siu A, Kimata C, Sawada H, Mak V, Lim S
Arthritis Care Res (Hoboken)
. 2024 Jan;
76(5):712-719.
PMID: 38163751
Objective: The purpose of this study was to investigate differences in clinical characteristics and health care use of Native Hawaiian and White patients with gout. Methods: We performed a retrospective...
9.
Lim S, Bolster M
Int J Womens Health
. 2022 Dec;
14:1733-1747.
PMID: 36544862
As one of the most potent osteoanabolic agents with a unique mechanism of action, romosozumab has high efficacy for osteoporosis treatment. It is a monoclonal antibody against sclerostin, a natural...
10.
Lim S
Womens Health (Lond)
. 2022 Sep;
18:17455057221125577.
PMID: 36154750
Increased understanding of the Wnt signaling pathway has led to the development of romosozumab, one of the most potent osteoanabolic agents to date for osteoporosis treatment. Romosozumab is a monoclonal...